Peter Higgins

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky et al. · Gut · 2012 · 1.5K citations · Full text

Statins and the Risk of Colorectal Cancer

Jenny N. Poynter, Stephen B. Gruber, Peter Higgins et al. · New England Journal of Medicine · 2005 · 820 citations

A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

B. Joseph Elmunzer, James M. Scheiman, Glen A. Lehman et al. · New England Journal of Medicine · 2012 · 706 citations · Full text

A Primer on Effectiveness and Efficacy Trials

Amit G. Singal, Peter Higgins, Akbar K. Waljee · Clinical and Translational Gastroenterology · 2014 · 684 citations · Full text

Evidence-based Intervention, Effectiveness Research, Clinical Trials +16

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Silvio Danese, Séverine Vermeire, Wen Zhou et al. · The Lancet · 2022 · 544 citations

Anti-inflammatory, Systemic Treatment, Gastroenterology +7